Difference between revisions of "Team:Munich"

Line 13: Line 13:
 
     #bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; }
 
     #bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; }
  
−
#iframe{
 
−
height: 100vh;
 
−
overflow: auto;
 
−
 
−
 
−
}
 
  
 
#HQ_page #myFooter td{
 
#HQ_page #myFooter td{
Line 1,079: Line 1,073:
 
<!-- Content -->
 
<!-- Content -->
 
<tr><td width="100%" colspan=3>
 
<tr><td width="100%" colspan=3>
−
<div id="iframe">
+
 
 
<table width=100% height=100% cellpadding=0 cellspacing=0 border=0>
 
<table width=100% height=100% cellpadding=0 cellspacing=0 border=0>
 
<tr>
 
<tr>
Line 1,218: Line 1,212:
 
</tr>
 
</tr>
 
</table>
 
</table>
−
</div>
 
 
</body>
 
</body>
 
</td></tr>
 
</td></tr>

Revision as of 13:19, 14 September 2017


Abstract

The ongoing crisis of increasing antibiotic resistance demands innovative preventive strategies. Recently, the RNA-targeting protein CRISPR-Cas13a has been used for highly sensitive DNA and RNA detection, promising diverse applications in point-of-care diagnostics. We integrated Cas13a in the detection unit of CascAID, our GMO-free diagnostic platform. CascAID combines an automated microfluidic device for rapid lysis and extraction of nucleic acids with a paper-based readout system. We demonstrated the performance of our device by targeting the 16S RNA from E. coli. We improved the detection limit of our platform, using simulations to optimize our amplification scheme and the final readout.

Conceived as a distributable platform for rapid point-of-care diagnostics, CascAID can be used to distinguish between bacterial and viral infections, thus minimizing the widespread use of antibiotics.

Furthermore, Cas13a allows the fast design of target sequences, making our system adaptive to the emergence of new viral outbreaks or fast mutating pathogens.

| The iGem Munich 2017 Team | 2017.07.13 |